ALLIANCE PHARMA PLC

Director's Dealing • Jan 23, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8873N

Alliance Pharma PLC

23 January 2019

	23 January 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 22 January 2019 that on 22 January 2019 Richard Jones, a Non-Executive Director of the Company, purchased 15,000 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 65.28 pence per share.

Following this transaction, Mr Jones' total beneficial interest in the Company is 15,000 Ordinary Shares, representing less than 0.01% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Richard Jones
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma Plc
b)	Legal Entity Identifier	213800RYIWZA4Q5WPZ13
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB0031030819
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
65.28p	15,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	n/a
f)	Date of the transaction	22 January 2019
g)	Place of the transaction	London Stock Exchange, AIM

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / David Herring

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:  www.alliancepharmaceuticals.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHUORRRKOAAUAR